NAD 1000mg

This guide covers the 1000mg vial format of NAD+ — the same dinucleotide coenzyme described in the dedicated 500mg guide (nicotinamide adenine dinucleotide, MW ~663.4 g/mol, formula C21H27N7O14P2), supplied at double the per-vial content. The molecule, its central role in cellular redox chemistry, and the proposed research mechanisms are identical to the 500mg form. What this guide adds is the practical context for protocols that consume more than 500mg before the reconstituted solution's stability window closes — and the specific stability-related reasons why a larger NAD+ vial benefits more than a larger peptide vial would.

NAD+ research at scale has a distinctive profile compared to peptide research: per-experiment quantities tend to be larger because cellular NAD+ pools are themselves substantial, and protocols studying sustained NAD+ availability rather than transient pulses consume more material. Extended-timepoint animal studies, multi-subject cohort work, and scaled-up in-vitro experiments examining NAD+-dependent enzyme activity (sirtuins, PARPs, CD38) all benefit from the larger vial format. The 1000mg vial reduces the number of reconstitution events across a study, which matters for NAD+ specifically — see the next section.

NAD+ 1000mg is sold strictly for laboratory and research use. It is not approved by the FDA or any other regulatory body for human or veterinary use, and nothing in this guide constitutes guidance for human administration.

Lyophilized peptides are stable at -20°C across long timeframes; the limiting factor on a vial's useful life is typically the post-reconstitution stability window. NAD+ has a different problem: even in the dry state, NAD+ is hygroscopic and somewhat unstable, with slow equilibration toward its reduced form NADH and toward degradation products like ADP-ribose under suboptimal storage. Every reconstitution event introduces a brief exposure to ambient air and moisture; the 1000mg vial reduces the number of those events across a research protocol, which means the supplied material spends less cumulative time outside ideal conditions. For NAD+ this is a meaningful stability benefit, not just a convenience benefit.

Every batch of MHS Longevity NAD+ 1000mg is submitted to an independent third-party laboratory before release — the same HPLC + Mass Spectrometry protocol applied to the 500mg vial:

Lyophilized NAD+ at -20°C is more sensitive to handling than most peptide products at the same temperature. For the 1000mg vial, immediate aliquoting after reconstitution becomes particularly important — the larger working volume yields more material that would otherwise sit in solution and equilibrate toward NADH. Aliquot into single-use volumes at -20°C, work under low-oxygen conditions where the protocol allows, and protect from light and moisture throughout handling. Standard aseptic technique applies.